Lauren Loss
Neurology · le Roy, NYNPI 1942576038
Payments from drug & device makers
Across 152 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$695
- Biogen$290
- Lilly USA, LLC$252
- Avanir Pharmaceuticals, Inc.$181
- Biohaven Pharmaceutical Holding Company Ltd.$165
- Pfizer$104
- plus $591 from 15 others
What the payments were for
- Food & beverage$2,20997%
- Education$703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 47 | $695 |
| Biogen | 15 | $290 |
| Lilly USA, LLC | 17 | $252 |
| Avanir Pharmaceuticals, Inc. | 17 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $165 |
| Pfizer | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Biohaven Pharmaceuticals, Inc. | 5 | $85 |
| AbbVie(2 entities) | 4 | $71 |
| Acadia Pharmaceuticals Inc | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Upsher-smith Laboratories LLC | 2 | $39 |
| Livanova USA, Inc. | 2 | $39 |
| Amgen | 2 | $31 |
| MDD US Operations, LLC | 2 | $30 |
| Neuronetics, Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Promius Pharma LLC | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Adamas Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,279 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 13 | $17,872 |
| Baclofen | 16 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $104 | $17,87213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.
Other neurology in le Roy
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
- Krupa PandeyAlbany$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.